Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Vivos Therapeutics (VVOS) to $2.50 from $7 and keeps a Buy rating on the shares following the 2025 earnings report. The firm believes share dilution “may be inevitable” as Vivos requires additional capital to fund operations and service the outstanding debt. The analyst is “cautiously optimistic” the company’s operational efficiency could improve and revenue could continue to grow in 2026.